Efficacy and safety of nebivolol combined with valsartan in patients with essential hypertension

Objective To evaluate the efficacy and safety of nebivolol combined with valsartan in patients with essential hypertension. Methods Totally 98 patients with essential hypertension were randomly divided into a control group and a treatment group: patients in the control group received valsartan, and those in the treatment group got nebivolol combined with valsartan. The clinical efficacy and adverse reaction of the 2 groups were compared 2 months later. Results After 8 weeks, the total efficacy rate of the treatment group was 95.9% and that of the control group was 79.6%, with significant difference(P 0.05); The systolic blood pressure, diastolic blood pressure and resting heart rate of the treatment group were significantly lower than those of the control group, with significant difference(P 0.05); The blood pressure control rate of the treatment group was significantly higher than that of the control group(P 0.05); The adverse reaction rate of the treatment group was 6.1% while that for the control group was 4.1%, with no significant difference between the 2 groups(P 0.05). Conclusion Nebivolol combined with valsartan for essential hypertension is safe and effective, which can be applied in clinical practice.